News
Supernus Pharma to Buy Sage Therapeutics for Up to $795 Million
Supernus Pharmaceuticals agreed to buy Sage Therapeutics for $8.50 a share in cash, equal to a total price of about $561 million at closing. The deal additionally includes a contingent value right that would entitle Sage shareholders to receive up to an additional $3.
ALBANY – Russell Sage College men’s lacrosse long-stick midfielder, South Glens Falls High School graduate, Joe Johnson, of ...
Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...
Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million, gaining access to the only ...
Russell Sage College field fockey had four student-athletes: junior midfielder Tayler Haslob, sophomore midfielder Cheyanne ...
Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...
After rejecting a buyout offer from its partner Biogen, the Cambridge firm is being acquired by Supernus Pharmaceuticals.
Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...
Two certified nurse practitioners and professors from Russell Sage College have returned from their annual mission trip to ...
This year's Head of School award went to graduating seniors Fiori Lee of Irvine and Courtney Tetteh-Martey of Newport Coast ...
Kristen Ford, Rachael Sage, Carissa Johnson, and Sarah Donner will play Electric Haze stage on June 22. Tickets cost $15 ...
The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback